"It's important to note that I believe the company has known that the Multiple Injections were the blowout treatment but the FDA wanted the single injection Step Study done first."
Why is what you BELIEVE important?
"The results from the MI study are so overwhelming that there is no question in my mind that the FDA is going to allow that data from the current study underway for the BLA filing."
There are results from the MI study? Those are more important than what You Believe, where can they be found?
"Even though the initial data was for a small number of 7 patients, the data was so extreme that I am confident it will repeat with larger patient numbers."
From the study-
Phase I will analyze safety and, as the study will be open label, no placebo will be used. All patients will receive a 4ml dose of Ampion™ (N=7).
Phase II will evaluate efficacy, cartilage formation as well as safety and the patients will be randomized 1:1, Ampion™ vs. Saline. This second phase will begin after the Phase I safety data is analyzed. (N=30).
Hallelujah, all 7 patients survived. To be "extreme" you must have been expecting the other result.
"Coupled with the fact that the company experienced very serious consequences from the most minor and unexpected procedures, I believe the company is much stronger today to never repeat those kind of mistakes."
Without the, ahem, "unexpected procedures" to hide behind the company would have suffered even more serious consequences. What makes you think that learning to hide bad data isn't a lesson they had already learned?
You mean the CC that was emailed to a select few...stop bashing and do some DD. I'm sick peeps saying this stuff...yes CC and yes Citi report. Get with the game dippies.
ENGLEWOOD, CO., September 15, 2014 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that its September 20, 2014 annual meeting of shareholders will be shared live through a webcast. This webcast will provide audio throughout supplemented by video of the slides and videos supporting presentations by management as well as the direct reports of clinical investigators that have participated in past (single injection) and ongoing (multiple injection) AmpionTM clinical trials.
The live audio webcast will be held on Saturday, September 20, 2014 at 10:00 a.m. MT / 12:00 p.m. ET. The webcast can be accessed at http://ampiopharma.equisolvewebcast.com/agm-2014 or via the Investors section of Ampio's corporate web site at www.ampiopharma.com. Web participants are encouraged to go to the web site 15 minutes prior to the start of the event to register, download and install any necessary software. A replay of the webcast will be available until October 20, 2014.